PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 171 filers reported holding PROTAGONIST THERAPEUTICS INC in Q2 2023. The put-call ratio across all filers is 0.41 and the average weighting 0.3%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $55,911 | -31.7% | 3,352 | +13.1% | 0.00% | -25.0% |
| Q2 2023 | $81,838 | +41.2% | 2,963 | +17.6% | 0.00% | +33.3% |
| Q1 2023 | $57,960 | +81.9% | 2,520 | -13.7% | 0.00% | +200.0% |
| Q4 2022 | $31,868 | +29.4% | 2,921 | 0.0% | 0.00% | 0.0% |
| Q3 2022 | $24,624 | +6.6% | 2,921 | 0.0% | 0.00% | 0.0% |
| Q2 2022 | $23,105 | -66.6% | 2,921 | 0.0% | 0.00% | -50.0% |
| Q1 2022 | $69,169 | -82.8% | 2,921 | -75.1% | 0.00% | -60.0% |
| Q4 2021 | $401,747 | +93.0% | 11,747 | 0.0% | 0.01% | +66.7% |
| Q3 2021 | $208,157 | -59.9% | 11,747 | +1.7% | 0.00% | -57.1% |
| Q2 2021 | $518,454 | +115.6% | 11,552 | +24.4% | 0.01% | +75.0% |
| Q1 2021 | $240,456 | +28.5% | 9,284 | 0.0% | 0.00% | +33.3% |
| Q4 2020 | $187,165 | +3.1% | 9,284 | 0.0% | 0.00% | 0.0% |
| Q3 2020 | $181,502 | +37.9% | 9,284 | +24.5% | 0.00% | +50.0% |
| Q2 2020 | $131,655 | +65.7% | 7,455 | +12.7% | 0.00% | +100.0% |
| Q3 2019 | $79,470 | – | 6,617 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
| Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
| Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
| RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
| Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
| Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
| Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
| FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
| PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
| FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |